Cancer name Kidney Renal Clear Cell Carcinoma
Cancer Type KIRC
Immunotherapy type Oncolytic viruses
Treatment WR.TK-HPGD+
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature lift-1
Official Symbol NA
Mode of action TRAN_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description As expected, WR.TK- infection resulted in an increase in the type Iinterferon (IFN) response, seen with increased lift-1 and lift-2 expression. However, this was not increased further with HPGD expression, indicating that HPGD does not enhance the innate immune response that might be expected to reduce viral oncolytic effect sand mediate premature viral clearance from the tumor. Instead, HPGD expression significantly increased the level of IFNγ produced within the tumor.
PMID 27374223
Title Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy